首页> 外文期刊>ACP Journal Club >Initial combination therapy with prednisone or infliximab improved outcomes in early rheumatoid arthritis more than DMARDs alone
【24h】

Initial combination therapy with prednisone or infliximab improved outcomes in early rheumatoid arthritis more than DMARDs alone

机译:泼尼松或英夫利昔单抗的初始联合治疗比单独使用DMARD更能改善早期类风湿关节炎的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

QuestionnnIn patients with early rheumatoid arthritis (RA), which treatment regimen is most effective for prevention of joint damage and functional decline? nnMethodsnnDesign: Randomized controlled trial.nnAllocation: Concealed.*nnBlinding: Blinded (outcome assessors).*nnFollow-up period: 1 year.nnSetting: 20 hospitals in western Netherlands.nnPatients: 508 patients 18 years of age (mean age 54 y, 68% women) with active RA for 2 years and no previous treatment with a disease-modifying antirheumatic drug (DMARD).nnIntervention: Group 1 (n = 126): sequential monotherapy with methotrexate (MTX) 15 mg/wk, followed stepwise, if Disease Activity Score in 44 joints (DAS44) > 2.4, by MTX 25 to 30 mg/wk, then monotherapy with sulfasalazine (SSZ) 2000 to 3000 mg/d, and then leflunomide 20 mg/d. Group 2 (n = 121): step-up combination therapy starting with MTX as above, then, if DAS44 still > 2.4, addition of SSZ, then hydroxychloroquine 400 mg/d, and then prednisone 7.5 mg/d. Group 3 (n = 133): combined therapy with prednisone 60 mg/d (tapered in 7 wk to 7.5 mg/d), MTX 7.5 mg/wk (increased to 25 to 30 mg/wk if DAS44 > 2.4), and SSZ 2000 mg/d. Group 4 (n = 128): combined therapy with infliximab 3 mg/kg at week 0, 2, and 6, then every 8 weeks (dose was increased stepwise if DAS44 > 2.4, up to 10 mg/kg) and MTX 25 to 30 mg/wk. Treatment adjustments were guided by DAS44, which was measured every 3 months. For responding patients, drugs were tapered to monotherapy at a maintenance dose; treatment could be reintroduced if disease activity flared.nnOutcomes: Change in joint damage in the hands and feet assessed by radiography (erosion score [0 to 280], joint space narrowing score [0 to 168], and total of the 2 scores), functional disability (assessed by the Health Assessment Questionnaire [0 to 3]), clinical remission (DAS44 < 1.6), and adverse events.nnPatient follow-up: 92% to 97% (intention-to-treat analysis).
机译:在患有早期类风湿关节炎(RA)的患者中,哪种治疗方案对预防关节损伤和功能衰退最有效? nn方法nn设计:随机对照试验nn分配:隐蔽* nn盲:盲(结果评估者)* nn随访时间:1年nn地点:荷兰西部20所医院68%的女性)活动期为2年,且之前未使用过抗病风湿药(DMARD)进行过治疗.nn干预:第1组(n = 126):依次进行甲氨蝶呤(MTX)15 mg / wk的单药治疗,然后逐步治疗,如果44个关节的疾病活动评分(DAS44)> 2.4,MTX 25至30 mg / wk,则单用磺胺丁嗪(SSZ)2000至3000 mg / d,然后来氟米特20 mg / d。第2组(n = 121):从上述MTX开始进行逐步联合治疗,然后,如果DAS44仍> 2.4,则加入SSZ,然后加入羟氯喹400 mg / d,然后泼尼松7.5 mg / d。第3组(n = 133):泼尼松60 mg / d(从7周到7.5 mg / d逐渐减少),MTX 7.5 mg / wk(如果DAS44> 2.4增加到25至30 mg / wk)和SSZ联合治疗2000毫克/天。第4组(n = 128):在第0、2和6周与英夫利昔单抗3 mg / kg联合治疗,然后每8周(如果DAS44> 2.4,剂量逐步增加),最高为25 mg / kg。 30毫克/周。 DAS44指导治疗调整,每3个月进行一次测量。对于有反应的患者,药物以维持剂量逐渐减少为单一疗法。如果疾病活动加剧,则可以重新开始治疗。nn结果:通过射线照相术评估的手和脚关节损伤的变化(侵蚀评分[0至280],关节间隙狭窄评分[0至168],以及这2个评分的总和),功能障碍(由健康评估问卷[0至3]评估),临床缓解(DAS44 <1.6)和不良事件。患者随访:92%至97%(意向性治疗分析)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号